全文获取类型
收费全文 | 1133篇 |
免费 | 85篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 32篇 |
妇产科学 | 61篇 |
基础医学 | 91篇 |
口腔科学 | 9篇 |
临床医学 | 49篇 |
内科学 | 194篇 |
皮肤病学 | 4篇 |
神经病学 | 6篇 |
特种医学 | 69篇 |
外科学 | 630篇 |
综合类 | 26篇 |
预防医学 | 8篇 |
眼科学 | 2篇 |
药学 | 18篇 |
中国医学 | 3篇 |
肿瘤学 | 15篇 |
出版年
2016年 | 6篇 |
2015年 | 6篇 |
2013年 | 10篇 |
2012年 | 6篇 |
2010年 | 5篇 |
2009年 | 5篇 |
2008年 | 10篇 |
2007年 | 15篇 |
2006年 | 13篇 |
2005年 | 12篇 |
2004年 | 9篇 |
2003年 | 9篇 |
2002年 | 13篇 |
2001年 | 21篇 |
2000年 | 31篇 |
1999年 | 46篇 |
1998年 | 23篇 |
1997年 | 22篇 |
1996年 | 20篇 |
1995年 | 27篇 |
1994年 | 21篇 |
1993年 | 33篇 |
1992年 | 71篇 |
1991年 | 119篇 |
1990年 | 92篇 |
1989年 | 77篇 |
1988年 | 60篇 |
1987年 | 48篇 |
1986年 | 36篇 |
1985年 | 39篇 |
1984年 | 21篇 |
1983年 | 22篇 |
1982年 | 7篇 |
1980年 | 11篇 |
1979年 | 17篇 |
1978年 | 13篇 |
1977年 | 17篇 |
1976年 | 6篇 |
1975年 | 12篇 |
1974年 | 9篇 |
1973年 | 14篇 |
1972年 | 17篇 |
1971年 | 21篇 |
1970年 | 24篇 |
1969年 | 12篇 |
1968年 | 17篇 |
1967年 | 11篇 |
1966年 | 11篇 |
1957年 | 6篇 |
1954年 | 5篇 |
排序方式: 共有1219条查询结果,搜索用时 15 毫秒
11.
Right trisegmentectomy with a synthetic vena cava graft 总被引:2,自引:0,他引:2
In the course of a right trisegmentectomy of the liver, nearly the entire length of the retrohepatic vena cava was replaced with a Dacron graft. Patency of the graft was proved by a venacavogram a year later. 相似文献
12.
13.
Cyclosporine and its metabolites in mother and baby 总被引:3,自引:0,他引:3
R Venkataramanan B Koneru C C Wang G J Burckart S N Caritis T E Starzl 《Transplantation》1988,46(3):468-469
14.
15.
16.
17.
H Furukawa O Imventarza R Venkataramanan M Suzuki Y Zhu V S Warty J Fung S Todo T E Starzl 《Transplantation》1992,53(4):722-725
Mongrel or beagle dogs were submitted to bile duct ligation, or to extraenteric biliary diversion by means of choledochoureterostomy. The kinetics of intravenously administered FK506 was not changed from control status two weeks after bile duct ligation, but the bioavailability of orally administered FK506 was nearly quadrupled. Following oral administration, the absorption of FK506 was highly variable. The results indicate that in dogs FK506 is absorbed from the intestine just as efficiently in the absence of enteric bile and in presence of exogenous bile salt supplement when compared with its absorption in presence of normal bile drainage. These findings with FK506 are different from those with cyclosporine after biliary obstruction or diversion and will have important practical as well as experimental ramifications. 相似文献
18.
19.
Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Annals of surgery》网站下载免费的PDF全文](/ch/ext_images/free.gif)
S Todo J J Fung T E Starzl A Tzakis H Doyle K Abu-Elmagd A Jain R Selby O Bronsther W Marsh et al. 《Annals of surgery》1994,220(3):297-309
OBJECTIVE: The efficacy for primary orthotopic liver transplantation of a new immunosuppressive agent, FK 506 (tacrolimus, Prograf, Fujisawa USA, Deerfield, IL), was determined. SUMMARY BACKGROUND DATA: After 3 years of preclinical research, a clinical trial of FK 506 for orthotopic liver transplantation was begun in February 1989, first as a rescue therapy for patients with intractable rejection with conventional immunosuppression, then as a primary drug. METHODS: Between August 1989 and December 1993, 1391 recipients (1188 adult and 203 pediatric) of primary liver allografts were treated with FK 506 from the outset. Results from these patients were analyzed and compared with those of 1212 historical control patients (971 adult and 241 pediatric) given cyclosporine-based immunosuppression. RESULTS: Actuarial survival at 4 years was 86.2% with FK 506 versus 65.5% with cyclosporine in the pediatric patients (p < 0.0000) and 71.4% versus 65.5% in the adults (p < 0.0005). The need for retransplantation was reduced significantly for FK 506 patients. Four-year graft survival was 77.0% with FK 506 versus 48.4% with cyclosporine in the pediatric patients (p < 0.0000), and 61.9% with FK 506 versus 51.4% with cyclosporine in the adult recipients (p < 0.0000). Regression analysis revealed that reduction in mortality or graft loss from uncontrollable rejection, sepsis, technical failure, and recurrent original liver disease were responsible for the improved results with FK 506 therapy. CONCLUSIONS: FK 506 is a potent and superior immunosuppressive agent for orthotopic liver transplantation. 相似文献
20.